Indian pharmaceutical leaders are expressing significant concerns regarding the proposed US tariffs on generic drugs, which could rise to 200% within a few years, deeming them unmanageable for manufacturers operating on tight margins.
Recently, US President Donald Trump outlined a tariff plan that would initially impose zero tariffs on generic drugs imported into the US for two years, followed by a gradual increase to 100% in the third year and 200% from the fourth year onward. This initiative aims to encourage the relocation of generic drug production back to the United States, while leaving existing policies on patented and innovative drugs unchanged.
Industry leaders, including Pharmexcil Chairman Namit Joshi, argue that establishing the necessary infrastructure for a generic pharmaceutical ecosystem in the US within two years is unrealistic. Joshi emphasized that the Indian pharmaceutical sector operates on extremely thin margins, making it impossible to absorb such high tariffs without passing the costs onto consumers or facing supply constraints.
Indian Pharmaceutical Alliance Secretary General Sudarshan Jain noted that while the tariffs will not take effect immediately, ongoing discussions with US authorities are critical. He highlighted that Indian manufacturers supply a significant portion of generic medications to the US, which are essential for maintaining healthcare security. Jain also pointed out the economic challenges of producing low-cost generics domestically in the US, suggesting that manufacturing in India remains more viable for many products.
The proposed tariffs raise important questions about the future of the generic drug market and the implications for healthcare costs in the US. As the Indian pharmaceutical industry continues to engage with US policymakers, the potential for increased costs and reduced access to essential medications looms large, highlighting the need for a balanced approach that considers both economic viability and public health needs.